Overview
Autoimmune skin diseases encompass a range of conditions characterized by immune system attacks on skin structures, including blistering diseases (e.g., bullous pemphigoid, pemphigus), inflammatory disorders (e.g., lichen planus, dermatomyositis), and systemic manifestations (e.g., systemic lupus erythematosus) 1247.Diagnosis
Clinical Presentation: Characteristic skin lesions and symptoms specific to the disease (e.g., blisters, rashes, ulcers) 147.
Histopathology: Biopsy findings confirm diagnosis in many cases (e.g., subepidermal blisters in bullous pemphigoid, acantholysis in pemphigus) 14.
Immunologic Tests: Antibody detection (e.g., indirect immunofluorescence, ELISA for specific autoantibodies) 147.
Imaging: Optical coherence tomography (OCT) for detailed imaging of inflammatory processes and blister levels 3.Management
First-Line Treatments:
- Topical Corticosteroids: For localized conditions like lichen sclerosus and initial treatment in elderly patients 7.
- Oral Corticosteroids: Effective for severe cases of bullous pemphigoid and pemphigus 7.
Adjunctive Therapies:
- Immunosuppressants: Azathioprine, mycophenolate mofetil, and methotrexate for chronic conditions 7.
- Intravenous Immunoglobulins (IVIg): For severe autoimmune skin diseases and toxic epidermal necrolysis 6 (Evidence: Expert opinion).
- Vitamin D Analogs: Potential therapeutic targets in immune-related dermatoses, though specific dosing not detailed 2.Special Populations
Elderly: Increased susceptibility to autoimmune skin diseases; preference for high-potency topical corticosteroids over oral prednisolone 7.
Comorbidities: Consideration of HIV status in sub-Saharan African populations, where autoimmune skin diseases may present differently 4.Key Recommendations
Utilize high-potency topical corticosteroids as initial treatment for elderly patients with autoimmune skin diseases to minimize systemic side effects (Evidence: Expert opinion).
Consider optical coherence tomography for detailed assessment and monitoring of inflammatory skin diseases, particularly autoimmune blistering conditions (Evidence: Expert opinion).
Evaluate the potential role of vitamin D analogs in managing immune-related cutaneous diseases, given their immunomodulatory effects, though specific clinical guidelines are lacking (Evidence: Moderate).
In severe cases, high-dose intravenous immunoglobulins can be considered as a therapeutic option, especially for rare autoimmune conditions and toxic epidermal necrolysis (Evidence: Expert opinion).References
1 Hinterseher J, Hertl M, Didona D. Autoimmune skin disorders and SARS-CoV-2 vaccination - a meta-analysis. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2023. link
2 Zeng Y, Yang S, Liu Y, Tang Z, Zong X, Li X et al.. The Role of VD/VDR Signaling Pathway in Autoimmune Skin Diseases. Mini reviews in medicinal chemistry 2023. link
3 Ha L, Hundt JE. Optical coherence tomography for fast bedside imaging, assessment and monitoring of autoimmune inflammatory skin diseases?. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2020. link
4 Madu PN, Williams VL, Noe MH, Omech BG, Kovarik CL, Wanat KA. Autoimmune skin disease among dermatology outpatients in Botswana: a retrospective review. International journal of dermatology 2019. link
5 Zivanovic D, Masirevic I, Ruzicka T, Braun-Falco M, Nikolic M. Pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) and polycystic ovary syndrome: Coincidentally or aetiologically connected?. The Australasian journal of dermatology 2017. link
6 Enk A, Fierlbeck G, French L, Hertl M, Messer G, Meurer M et al.. Use of high-dose immunoglobulins in dermatology. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2009. link
7 Loo WJ, Burrows NP. Management of autoimmune skin disorders in the elderly. Drugs & aging 2004. link